Drug Profile
Pinometostat - Epizyme
Alternative Names: EPZ-5676Latest Information Update: 22 Aug 2022
Price :
$50
*
At a glance
- Originator Epizyme
- Class Antineoplastics; Benzimidazoles; Cyclobutanes; Furans; Purines; Small molecules
- Mechanism of Action DOT1L protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute biphenotypic leukaemia
Most Recent Events
- 12 Aug 2022 Epizyme has been acquired by Ipsen
- 02 Jan 2021 Celgene Corporation terminates its collaboration agreement with Epizyme for Pinometostat
- 28 Apr 2020 No recent reports of development identified for phase-I development in Acute-biphenotypic-leukaemia(In adolescents, In children, In infants) in Canada (IV, Infusion)